Do you have a cite (for percentage of PD events that are new lesion among NSCLC patients treated with docetaxel)?
No cite. Based on my experience working with oncology trials, it should be less than 10%, although that percentage could be higher among patients with short PFS duration as discussed in the first reply.
Market Data 
Markets 
AI
